[go: up one dir, main page]

HK1000920A1 - N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives - Google Patents

N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives Download PDF

Info

Publication number
HK1000920A1
HK1000920A1 HK97102541A HK97102541A HK1000920A1 HK 1000920 A1 HK1000920 A1 HK 1000920A1 HK 97102541 A HK97102541 A HK 97102541A HK 97102541 A HK97102541 A HK 97102541A HK 1000920 A1 HK1000920 A1 HK 1000920A1
Authority
HK
Hong Kong
Prior art keywords
hydroxy
hydrogen
pyrimidin
ethyl
compound
Prior art date
Application number
HK97102541A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1000920B (en
Inventor
C. Taylor Edward
G. Kuhnt Dietmar
Shih Chuan
B. Grindey Gerald
Original Assignee
The Trustees Of Princeton University
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27503964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1000920(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/528,155 external-priority patent/US5028608A/en
Application filed by The Trustees Of Princeton University, Eli Lilly And Company filed Critical The Trustees Of Princeton University
Publication of HK1000920B publication Critical patent/HK1000920B/en
Publication of HK1000920A1 publication Critical patent/HK1000920A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK97102541A 1989-12-11 1997-12-22 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives HK1000920A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44874289A 1989-12-11 1989-12-11
US47965590A 1990-02-08 1990-02-08
US07/528,155 US5028608A (en) 1989-12-11 1990-05-24 N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
US07/528,805 US4996206A (en) 1989-12-11 1990-05-24 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives

Publications (2)

Publication Number Publication Date
HK1000920B HK1000920B (en) 1998-05-08
HK1000920A1 true HK1000920A1 (en) 1998-05-08

Family

ID=27503964

Family Applications (1)

Application Number Title Priority Date Filing Date
HK97102541A HK1000920A1 (en) 1989-12-11 1997-12-22 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives

Country Status (22)

Country Link
EP (1) EP0432677B1 (ja)
JP (1) JP3016876B2 (ja)
CN (1) CN1030608C (ja)
AR (1) AR245129A1 (ja)
AT (1) ATE135007T1 (ja)
AU (1) AU640182B2 (ja)
CA (1) CA2031890C (ja)
CY (1) CY2076B1 (ja)
DE (2) DE122005000012I2 (ja)
DK (1) DK0432677T3 (ja)
ES (1) ES2084639T4 (ja)
GR (1) GR3019784T3 (ja)
HK (1) HK1000920A1 (ja)
HU (1) HU218483B (ja)
IE (1) IE904445A1 (ja)
IL (1) IL96531A (ja)
LU (1) LU91147I2 (ja)
NL (1) NL300181I2 (ja)
NZ (1) NZ236385A (ja)
PT (1) PT96140B (ja)
RU (1) RU2057131C9 (ja)
SG (1) SG48098A1 (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254687A (en) 1991-12-04 1993-10-19 The Trustees Of Princeton University Process for the preparation of pyrrolo[2,3-d]pyrimidines
US5235053A (en) * 1992-06-22 1993-08-10 Eli Lilly And Company Process for the synthesis of 4-hydroxy-5-halopyrrold[2,3-d]pyrimidine intermediates
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
CN100344615C (zh) * 2004-11-25 2007-10-24 重庆医药工业研究院有限责任公司 制备N－(吡咯并[2,3－d]嘧啶－5－基)酰基谷氨酸衍生物的方法及中间体
CN101146532B (zh) 2005-01-21 2012-05-09 阿斯泰克斯治疗有限公司 药物化合物
KR101359838B1 (ko) 2006-08-14 2014-02-07 시코르, 인크. 페메트렉세드 이산의 결정형 및 이의 제조 방법
TWI377955B (en) 2006-08-14 2012-12-01 Sicor Inc Processes for preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
WO2008021410A2 (en) 2006-08-14 2008-02-21 Sicor Inc. Highly pure pemetrexed diacid and processes for the preparation thereof
TWI374886B (en) 2006-08-14 2012-10-21 Sicor Inc Processes for preparing intermediates of pemetrexed
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
MX338047B (es) * 2008-06-06 2016-03-31 Boehringer Ingelheim Int Combinacion farmaceutica útil para el tratamiento fr enfermedades que involucran proliferación celular, migración o apoptosis de células de mieloma, angiogéneisis o fibrosis.
AU2015210337B2 (en) * 2008-06-06 2017-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical combination
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
WO2011064256A1 (en) 2009-11-24 2011-06-03 Azad Pharmaceutical Ingredients Ag A new crystalline form of pemetrexed disodium
LT2854768T (lt) 2012-05-30 2017-06-12 Fresenius Kabi Oncology Limited Pemetreksedo farmacinės kompozicijos
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
WO2014167585A1 (en) 2013-04-12 2014-10-16 Actavis Group Ptc Ehf. Pemetrexed formulation
EP2997031A1 (en) 2013-05-17 2016-03-23 Instytut Farmaceutyczny Process for the preparation of high purity amorphous pemetrexed disodium and crystalline forms of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid
EP3008064B1 (en) 2013-06-14 2017-11-22 Synthon B.V. Stable pemetrexed arginine salt and compositions comprising it
JP2016527227A (ja) * 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
NZ630292A (en) 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
US20180235969A1 (en) 2014-10-16 2018-08-23 Synthon B.V. Liquid pharmaceutical composition comprising pemetrexed
CN104672241B (zh) * 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA3017411C (en) 2016-03-15 2024-06-25 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2019046612A1 (en) * 2017-08-31 2019-03-07 Duquesne University Of The Holy Spirit INHIBITORS OF FIRST-CATEGORY SHMT2 AND MTHFD2 AS ANTI-TUMOR AGENTS
CN110305135B (zh) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305137A (zh) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305134B (zh) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305136A (zh) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818819A (en) * 1986-10-20 1989-04-04 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
DK172753B1 (da) * 1988-05-25 1999-06-28 Lilly Co Eli N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat
US4883799A (en) * 1988-06-29 1989-11-28 The Trustees Of Princeton University N-(4-(1-hydroxy-3-(5,6,7,8-tetrahydropyrido(2,3,-d)-pyrimidin-6-yl)prop-2-yl)benzoyl)glutamic acid derivatives

Also Published As

Publication number Publication date
RU2057131C9 (ru) 2006-04-10
PT96140A (pt) 1991-09-30
RU2057131C1 (ru) 1996-03-27
DK0432677T3 (da) 1996-04-09
AR245129A1 (es) 1993-12-30
NL300181I1 (nl) 2005-05-02
HU908147D0 (en) 1991-06-28
NZ236385A (en) 1992-05-26
EP0432677A1 (en) 1991-06-19
CN1055182A (zh) 1991-10-09
NL300181I2 (nl) 2005-06-01
CA2031890A1 (en) 1991-06-12
IL96531A0 (en) 1991-09-16
ES2084639T4 (es) 2013-06-11
AU6779190A (en) 1991-06-13
ATE135007T1 (de) 1996-03-15
JP3016876B2 (ja) 2000-03-06
AU640182B2 (en) 1993-08-19
DE122005000012I2 (de) 2006-02-09
ES2084639T3 (es) 1996-05-16
DE122005000012I1 (de) 2005-06-23
IL96531A (en) 1995-08-31
CA2031890C (en) 2000-07-25
CN1030608C (zh) 1996-01-03
CY2076B1 (en) 1998-09-11
EP0432677B1 (en) 1996-03-06
IE904445A1 (en) 1991-06-19
SG48098A1 (en) 1998-04-17
HU218483B (hu) 2000-09-28
LU91147I2 (fr) 2005-05-17
DE69025723T2 (de) 1996-10-31
JPH083166A (ja) 1996-01-09
DE69025723D1 (de) 1996-04-11
HUT58335A (en) 1992-02-28
PT96140B (pt) 1997-06-30
GR3019784T3 (en) 1996-07-31

Similar Documents

Publication Publication Date Title
EP0432677B1 (en) N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
HK1000920B (en) N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
US5344932A (en) N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives
US4996206A (en) N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
DeGraw et al. Synthesis and antifolate properties of 5, 10-ethano-5, 10-dideazaaminopterin
US4882334A (en) N-(5,6,7,8-tetrahydropyrido]2,3-d]pyrimidin-6-ylethl-thineyl-and furylcarbonyl)-glutamic acid derivatives
KR940002952B1 (ko) 피리도[2,3-d]피리미딘 유도체의 제조방법
US5223503A (en) 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents
CA1340792C (en) Pyrido[2,3-d]pyrimidine deratives
EP0255228B1 (en) 4(3h)-oxo-5,6,7,8,-tetrahydropyrido-(2,3-d)pyrimidine derivatives
US4833145A (en) 4(3H)-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine derivatives
US8518954B2 (en) Inhibitors of folic acid-dependent enzymes
US4526964A (en) 2,4-Diamino-6-(hydroxymethyl)pyrido[2,3-d]pyrimidine
EP0638079B1 (en) Deazaaminopterins for treatment of inflammation
EP0511792A2 (en) Pyridoprimidine derivatives as antineoplastic agents
US5536724A (en) Antiinflammatory and antineoplastic 5-deazaaminopterins and 5,10-dideazaaminopterins
EP0075880B1 (en) Pyrido (2,3-d) pyrimidines
HU211941A9 (hu) N-(pirrolo[2,3-d]pirimidin-3-ii-acil)-glutaminsav-származékok Az átmeneti oltalom az 1-7. igénypontokra vonatkozik.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)